Authors: Alice Greenway, Future Science Group
Since the introduction of the human papilloma virus (HPV) vaccine in England in 2008, Public Health England (PHE; London, UK) have reported an 86% decrease in HPV infections in women aged 16–21. With these promising results, experts predict that the vaccine could eventually lead to the eradication of cervical cancer.
In a recent study, published in The Journal of Infectious Diseases, PHE scientists report the prevalence of HPV in women attending chlamydia screening between 2010 and 2016.
To view restricted content, please:
